Intravenous administration of EGB 761 and 90-day functional outcome in patients with acute ischemic stroke
- Author:
Dong-Ick Shin
;
Hyung-Suk Lee
;
Shin-Hye Baek
;
Ho-Seong Han
;
Hye-Lim Lee
;
Yong-Dae Kim
- Publication Type:Journal Article
- MeSH:
Stroke
- From:Neurology Asia
2015;20(3):215-219
- CountryMalaysia
- Language:English
-
Abstract:
Background & Objective: EGB 761 is a standardized natural extract used to treat impaired cerebral
perfusion and nutrition (cerebrovascular insufficiency) in Korea. Although several animal studies have
been conducted, few studies have investigated the clinical effects of EGB 761 in acute stroke. This
study assessed the clinical benefit of intravenous EGB 761 in patients with acute ischemic stroke.
Methods: This retrospective study examined a prospectively collected stroke database. We evaluated
232 patients with acute ischemic stroke within 48 hours of symptom onset. All patients were treated
with antiplatelet or anticoagulation agents. We compared baseline characteristics between the EGB
761-treated and non-treated groups. The functional outcome measure was the modified Rankin Scale
(mRS) score 90 days after stroke onset. Results: Of the 232 patients, 170 received EGB 761 during the
first 3 days after arrival in the emergency department. We found no significant differences in baseline
characteristics between the groups, with the exception of atrial fibrillation (p=0.032). After adjusting
for baseline factors, intravenous administration of EGB 761 was associated with an improved 90-day
functional outcome (mRS ≤2) compared with the control group (odds ratio, 2.56; p<0.05).
Conclusions: Our results showed a clinical benefit of intravenous EGB 761 in patients with acute
ischemic stroke
- Full text:P020151007419151203575.pdf
